Garlic compound ajoene helps fight acute myeloid leukaemia 大蒜複合物阿霍烯有助於對抗急性髓細胞性白血病

Monday 04/05/2021 (jkzx.com) — Ajoene, a compound from Garlic (Allium Sativum) may be used to treat acute myeloid leukaemia (AML) because of its anti-leukemia activity, according to an editorial published in the journal Leukemia Research in 2004.

H.T. Hassan from University of Lincoln, author of the editorial says that the anti-tumor activity of garlic has been known for more than 3000 years.

Some sulfur compounds other than ajoene identified in garlic are already known for its effectiveness at inhibiting the proliferation and inducing apoptosis of several cancers such as breast cancer, bladder cancer, colorectal cancer, hepatic cancer, prostate cancer, lymphoma, and skin cancer.

The new compound known as ajoene (4,5,9-trithiadodeca-1,6,11-triene-9-oxide) can be produced efficiently from another sulfur compound isolated from garlic – allicin. It is only that ajoene is more stable than its precursor allicin which is desired.

Early studies show that ajoene can help thrombosis, bacterial infections, high cholesterol and skin cancer in patients. Ajoene
has been found to be able to inhibit proliferation and induce apoptosis of several human leukemia cell lines. And most recently it was found that ajoene could induce 30% apoptosis in myeloblasts from a patient with chronic myeloid leukemia.

Most recently researchers have found that ajoene can help boost the apoptosis of acute myeloid leukaemia induced by chemotherapy. Chemotherapy tends to cause some drug resistance in AML patients. Tests conducted with drug resistant AML cell cultures indicate that ajoene can enhance the apoptosis induced by chemotherapy in the treatment of refractory and/or relapsed AML patients and also elderly patients.

Garlic should be the number one anticancer food for every cancer patient. A patient who survived from brain cancer for 19 years considered garlic the most potent anti-cancer food.

H.T. Hassan (2004) Ajoene (natural garlic compound): a new anti-leukaemia agent for AML therapy, Leukemia Research, Volume 28, Issue 7, July 2004, Pages 667-671
https://doi.org/10.1016/j.leukres.2003.10.008